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We used a "high-performance" liquid-chromatographic assay [for parent cyclosporine (GsA) and nine metabolites] and a radioimmunoassay to detail the diversity of results among whole-blood samples from patients with transplanted organs.
Heterogeneous populations of metabolites in samples collected just before the next dose of GsA were detected by HPLC, with GsA, M17, Ml, or M8 predominating; M21, M203-218, MUNDF1, and M18 were detected in lesser amounts. Results by HPLC vs AlA for GsA or for individual metabolites vs GsA (or AlA) were diverse, with correlation coefficients (r) ranging from 0.058 to 0.933. AlA vs HPLC(sum of GsA + metabolites) gave the bestcomparison (slope = 0.931, y-intercept 14 p.gIL, r = 0.933); but the scatter ofdata aboutthe regression line remained significant = 132 jzg/L). Most important, R1AJHPLC(CsA) vs HPLC(sum of metabolites) was remarkably poor (r = 0.222).
A 12-h pharmacokinetic curve (for drug concentrations in a heart-transplant patient) displayed dissimilar times for peak concentrations of GsA and metabolites; each differed in the proportion (48% to 81% of peak concentration) eliminated from blood over the 12 h. These studies exemplify the utility of a more-inclusive, specific assay to monitor the diverse disposition of cyclosporines in patients and to demonstrate the errors associated with use of the RIA/HPLG ratio technique to predict metabolite concentrations.
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immunosuppressive drugs . chromatography, reversed-phase Routine RIA and "high-performance" liquid-chromatographic (HPLC) assays fail to describe completely and specifically the disposition of cyclospormne (CsA) parent drug and individual metabolites in blood/serum/plasma. Current assays are nonspecific or exclude the metabolites entirely (1). Recent evidence demonstrates that metabolites M17, Ml, and M21 are immunosuppressive in vitro (2, 3) and suggest that one or more metabolites may be toxic (4) . The diverse influences of drug interactions on metabolism of CsA (5), the effect of a 24-h circadian cycle on the metabolism and (or) absorption of CsA (6) , and the impact of the type of organ transplanted on the disposition of CsA (7) further necessitate a better insight into the pharmacokinetics of CsA for each patient. However, most assays preclude the selective measurement of CsA and individual metabolites. Often, to estimate the accumulation of"metabolites" in blood, the RIAJHPLC(CsA) ratio technique is used (8) . However, for some patients this ratio remains constant even though bilirubin concentrations, one indicator of heptotoxicity, may continue to rise (9 clinical data have been acquired for a variety of specimen types, with various handling protocols, dosing regimens, and analytical methods, such that overall comparison of these data is nearly impossible (10, 11) . We need to better address and control those variables if we are toenhance the usefulness of therapeutic monitoring of CsA.
In the preceding paper (12) we reported a discrete HPLC assay for CsA and individual metabolites. Here we describe the practical utility of this assay to monitor the diverse disposition of CsA in patients. To support our conclusions, we compare RIA and HPLC results for CsA in a series of samples collected daily from two transplant patients. We also document a 12-h pharmacokinetic proffle from one patient with a transplanted heart, and evaluate data from "trough" whole-blood samples-samples collected just before the next dose of C5A-by both RIA and the more inclusive HPLC assay.
Materials and Methods
All reagents, standards, and apparatus used here have Study B. Heparinized whole-blood samples from a patient with a transplantedheart who was taking a steady-state dose of 400mg of CsA (7.0 mg/kg, every 12 h) were collected hourly for 12 h and assayed by the more inclusive HPLC procedure (CsA + metabolites) and by RIA.
Study C. Heparinized whole-blood samples from patients with transplanted liver (n = 9),kidney (n = 36), bone marrow (n = 8), or heart (n = 3) were collected just before the next dose of CsA and assayed with the more inclusive HPLC procedure and by RIA. 
Results
Study A. Analytical results for "trough" whole-blood samples collected over several days from a liver-transplant patient and a heart-transplant patient are shown in Figure  1 . Clinically, the cardiac transplant patient displayed mild congestive heart failure (days 1 to 4), which resolved; concentrations of liver enzymes were slightly increased, and values for serum creatinine ranged from 12 to 35 mgfL. The liver-transplant patient had slightly increased concentrationsof liverenzymes (post transplant), which gradually decreased; serum creatinine ranged from 14 to 28 mg/L, and there was no evidence of cardiac failure. The RIA result ranged from 120% to 400% and from 108% to 1500% of the parent CsA value for the liver-and heart-transplant patients, respectively. Most important, irrespective of the type of transplant, the value from one assay could not be used to accurately predict the result of the other assay, nor could an algorithm be derived that would reliably estimate the amount of parent CsA (with or without metabolites) from the results of the other assay.
before next dose. The concentration of M8 changed very little during these 12 h. Study C. RIA and HPLC data for whole-blood samples from 56 patients were variable. Our comparisons of the data include: parent RIA vs CsA(HPLC) (Figure 3A) , HPLC(sum of CsA + metabolites) vs HPLC(CsA) (Figure 3B ), HPLC(sum of metabolites) vs RIA metabolites (Figure 3C) , and RIA vs HPLC(sum of CsA + metabolites) ( Figure 3D ). The "RIA metabolites" value was obtained by subtracting the CsA(HPLC) result from the RIA result. Comparisons of M17 vs CsA(HPLC), M17 vs the sum of CsA + metabolites(HPLC), and M17 vs RIA (Figure 4 ) also showed no 
'
Study B. A 14-h pharmacokinetic profile (Figure 2) demonstrates the disposition of CsA and metabolites Ml, M8, M17, M21, and MUNDF1 detected in the whole-blood samples of a patient with a transplanted heart. For each specimen we plotted, vs time, individual results for the parent CsA and each metabolite (by HPLC), the sum of these cyclosporines by HPLC, and the RIA results. For this patient, the concentration of parent CsA is about 68% of the RIA value; the sum of parent CsA and metabolites (by HPLC) is about 138% (range 112% to 154%) of the RIA value. Predominant metabolites include M17, Ml, and M8. The "trough" sample at 12 h showed the concentration of M17 > CsA > Ml> M8; M21 was <16 pgfL. The concentration of M17, Ml, and CsA decreased by 49%, 65%, and 81%, respectively, from the time of peak concentration to just M17, Ml, or M8 vs "RIA metabolites" [ Figure 4 (right) and Figure 6 ] were unremarkable and suggest that mathematical manipulations of RIA data to determine a value representative of prevailing metabolites are inappropriate.
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Discussion
Our data demonstrate that the RIAJHPLC ratio technique, often used to assess metabolite concentrations (14), is unreliable.
For those samples tested in this study, the ratios of results from RIAJHPLC(CsA only) ranged from 1.2 to 20 (mean 4.39) with CV = 75%. The ratios of RIAIHPLC(sum CsA + metabolites) were less diverse (range = 0.44 to 1.55, mean 0.96, CV -24%); however, the heterogeneous populations of metabolites could not be accurately assessed with this mathematical manipulation.
Most important, the poor correlation (r = 0.222, slope = 20. samples, but only at concentrations less than 31 ,u.gfL. M203-2l8 was detected in 41% of the samples, at concentrations ranging from <15 to 269 zg/L, and MUNDF1 was present in 30% of the samples, at <15 to 127 g/L. These data substantiate the diversity in the relative amounts and types of cyclosponnes in measured whole-blood samples collected 24-h post-dose. Results of the pharmacokinetic study further illustrate these dynamics and emphasize the importance of day-to-day consistency in time of dosing and specimen collection for uniform, interpretable results. We predicated our data on whole blood to minimize variability associated with sample handling for serum/plasma. Whether whole blood is the better sample remains to be determined.
In conclusion, we demonstrate that the analytical method must be specific to address accurately the diverse patterns of disposition of CsA and metabolites, irrespective of influences from sample type, handling protocol, dosing regimen, drug interactions, or type of organ transplanted. RIA was not useful for characterizing and quantifying the predominant metabolite(s) in a patient's whole blood. To concomitantly proffle CsA and each metabolite with one assay would make available to the clinician additional data for more effective dosing to maintain immunosuppression, poesibly to lessen the chance of toxicity, and perhaps to lower the cost of CsA therapy. Early detection of metabolic differences of CsA in patients would permit adjustment of dosage in a more timely fashion, thereby minimizing episodes of rejection or toxicity. At present, interpretation of individual metabolite concentrations in blood remains unclear and further in-depth investigation isrequired. A specific HPLC procedure, inclusive of metabolites, may be a better tool for describing the interrelationships ofCsA and metabolites in therapy and toxocity.
